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1. Introduction 
 (+)-Methamphetamine (METH) abuse is one of the most serious health problems 
in the United States and Europe due to its addictive properties and potential neurotoxic 
effects [1, 2, 3]. METH abuse appears to have stabilized or decreased slightly in the 
general populations, however abuse in certain populations is increasing [4, 5]. 
Treatments for drug abuse are often tested in animal behavioral pharmacology models. 
One of the first in vivo tests conducted in animals is to follow the concentration of the 
drug and its metabolites as a function of time. In this way, one can determine how long 
a potential medication must be active and one can decide if specific tissues are 
potentially better targets for medication.  
 Glucuronidation and sulfation are important phase II reactions in the 
biotransformation of xenobiotics for proper excretion from the body [6]. These phase II 
compounds are generally biologically less reactive than the parent molecules; however, 
some studies suggest that when conjugated, the compounds are more active than the 
parent molecules [7]. Compounds such as morphine-6β-glucuronide, a metabolite of 
morphine, and minoxidil sulfate, a metabolite of minoxidil, more commonly known as 
Rogaine, are examples where the phase II metabolites of these compounds are 
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bioactive [6, 7]. These studies show that in some cases, difference in potency between 
the parent and conjugated molecules can be up to 100-fold [6]. The biological activity of 
the phase II metabolites of methamphetamine is unknown. 
 For further research on the disposition of these compounds in the human body, 
standards must be available. Rats have been shown to undergo similar pathways as 
humans when metabolizing methamphetamine, only differing in the concentrations of 
the glucuronide and sulfate conjugates they produce [8]. Therefore, rats can be used to 
produce the standards. Isolation of the standards from rat urine can be performed by 
solid phase extraction. Further purification can be performed by a higher resolution 
liquid chromatography. Four different methods for solid phase extraction were evaluated 
for their ability to isolate glucuronide and sulfate metabolites of METH. Liquid 
chromatography with tandem mass spectrometry (LC-MS/MS) was used to evaluate the 
effectiveness of each isolation procedure.  
Figure 1: METH Metabolism in Humans and Rats 
                       
Proposed pathway for the metabolism of METH in rats and humans [8] 
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2. Methods 
 
2.1 Chemicals and reagents 
 The internal standard, Methamphetamine-D5, was purchased from Sigma (Saint 
Louis, MO). LC-MS grade methanol and acetonitrile were purchased from Fisher 
Scientific (Pittsburg, PA). Water was purified before use with a Millipore Milli-Q 
Synthesis A10 system (Millipore, Bedford, MA). All other reagents used were purchased 
from Fisher Scientific (Pittsburg, PA). 
 
2.2 Urine collection 
 Male Sprague Dawley rats were administered 10 mg/kg-day METH using 
subcutaneous osmotic minipumps. Rats were placed in metabolism cages for 4 days 
with free access to food and water. Urine samples were collected twice a day and 
stored at -20˚C. METH was obtained from the National Institute on Drug Abuse 
(Bethesda, MD). 
 
2.2 Extraction method 1 
 This extraction method was adapted from the Chen et al. method for sample 
preparation [9]. Sep-Pak C18 cartridges (1ml x 100mg) were pretreated with 10ml 
methanol, 5ml 25% of acetonitrile in 10mM phosphate buffer (pH 2.1), and 10ml distilled 
water. Urine (0.5ml) was mixed with 50μl of 4μg/ml of the internal standard 
methamphetamine-D5 and 3ml of 0.5M ammonium sulfate buffer (pH 9.3). The urine 
was then passed through a pretreated cartridge. The cartridge was washed with 5ml of 
5mM ammonium sulfate buffer (pH 9.3) and 0.5ml of distilled water.  The compounds 
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were then eluted with 2ml of 25% acetonitrile in 10mM phosphate buffer (pH 2.1). The 
eluate was mixed with 3ml of 0.5M ammonium sulfate buffer and passed through a new 
pretreated cartridge. The cartridge was washed with 5ml of 5mM ammonium sulfate 
buffer and 0.5ml of distilled water. The compounds were then eluted with 2ml of 
methanol and concentrated to about ~300μl under nitrogen stream at 40˚C. The sample 
was then injected into a small centrifuge tube and methanol was used to balance the 
volumes of the samples. After centrifuging for 5 min at 14000 rpm, the samples were 
analyzed using LC-MS/MS. 
 
2.3 Extraction method 2 
 Urine (0.5ml) was mixed with Ba(OH)2 starting at 100μl in the first sample then 
increased by 50μl in each sample up to 450μl in the last sample. The samples were 
centrifuged for five minutes at 14000 rpm. Sep-Pak C18 (1ml x 100mg) cartridges were 
pretreated with 10ml of methanol, 5ml of 25% acetonitrile in 10mM phosphate buffer 
(pH 2.1), and 10ml of distilled water. The samples were subjected to method 1 
extraction steps and analyzed using LC-MS/MS. 
 
2.4 Extraction method 3 
 Six Sep-Pak C18 cartridges were pretreated with 1.0ml of methanol and 2ml of 
50mM sodium dihydrogenphosphate adjusted to pH 7.0 with sodium hydroxide. Urine 
(0.5ml) was mixed with 0.1ml of 2.5mM sodium 1-heptanesulfonate and applied to a 
pretreated cartridge. The cartridges were rinsed twice with 0.5ml of 8% methanol in 
0.2M carbonate buffer (pH 11) and once with 0.5ml of 5% methanol in 50mM carbonate 
buffer (pH10). The compounds were then eluted with 300μl of 85% methanol in 2M 
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phosphoric acid. The samples were centrifuged for 5 minutes at 14000 rpm then 
analyzed using LC-MS/MS.  
 
2.4 Extraction method 4 
 This extraction method was adapted from the method described by Strahm et al. 
[10]. SPE Oasis WAX mixed-mode polymeric anion-exchange cartridges (6ml) were 
pretreated with 2ml of 2M acetate buffer (pH 5.2). Urine (4ml) was mixed with 2ml of 2M 
acetate buffer (pH 5.2) and passed through a pretreated cartridge. The cartridge was 
then washed with 2ml of distilled water. For the glucuronide fraction, the compounds 
were eluted with 8ml of methanol/formic acid 10% in water (95:5). The cartridge was 
then washed with 2ml of methanol/ammonium hydroxide 5% in water (20:80). The 
sulfates were then eluted using 8ml of methanol/ammonium hydroxide 5% in water 
(90:10). Both fractions were evaporated under a nitrogen stream to dryness. The 
glucuronide fraction was re-dissolved in 200μl of methanol/acetic acid 1% in water 
(50:50) and the sulfate fraction was re-dissolved in 200μl of methanol/acetic acid 1% in 
water (20:80). The samples were analyzed by LC-MS/MS. 
 
2.5 Acid Hydrolysis 
 This experiment was adapted from the Kazuaki Shimosato et al. method for 
hydrolysis of the conjugates [11]. Urine (1ml) was mixed with 1ml of 12M hydrochloric 
acid and incubated at 60˚C for 4 hours while sonicating. The samples were then mixed 
with 2ml of 2M acetate buffer (pH 5.2) and the pH of the sample was adjusted to 
approximately 5 using sodium hydroxide. Controls were then prepared using 1ml of 
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water and 2ml of 2M acetate buffer (pH5.2). Method 4 extraction was then performed on 
the samples and the fractions were analyzed using LC-MS/MS. 
 
2.6 Blank Urine Samples 
 In order to determine whether or not the compounds detected were endogenous  
or were the result of dosage with METH, a method 4 extraction was performed on rat 
urine from rats that were not administered METH. The samples were then analyzed 
using LC-MS/MS. 
 
2.7 Instrumentation 
 The LC system used was a Shimadzu LC 10AD paired to a Shimadzu SIL-HTA 
autosampler. The mass spectrometer used was a Quattro Premier triple-quadrupole 
fitted with a Z-spray interface with an ESI source operating in positive ion mode. A 
phenyl-hexyl-column maintained at 35˚C was used for separation. Mobile phase A was 
20mM ammonium formate (pH 2.7) with 28% acetonitrile and mobile phase B was 
20mM ammonium formate (pH2.7) with 95% acetonitrile. The flow rate was 0.4 ml/min. 
The linear gradient was as follows: 0 - 3 min, 0% B; 3 – 5 min: 0% B; 5 – 8 min: 100% 
B; 8 – 11 min: 100% B. The MS/MS experiments were performed by collision-induced 
dissociation with argon as the target gas (2 x 10-3 torr). METH-4-O-Glucuronide, METH-
4-O-Sulfate, METH-D5, METH, AMP, 4-OH-METH, and 4-OH-AMP were quantitated 
using the following precursor → product m/z values: 342 → 166, 245.1 → 165.1, 155.1 
→ 92.2, 150.2 → 91, 136 → 91, 166 → 107.2, and 152 → 107 respectively. 
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3. Results 
 
3.1 Method 1 results 
 For method 1, the mass spectrometer was set to detect peaks of METH-4-O-
glucuronide, 4-OH-METH, METH-D5, 4-OH-AMP, METH, and AMP. The chromatogram 
of a method 1 extracted sample is shown in Figure 2.  
 
Figure 2: Chromatogram for method 1 extraction 
Urine hph gluc01-2
Time
1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00
%
0
100
1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00
%
0
100
1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00
%
0
100
1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00
%
0
100
1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00
%
0
100
1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00
%
0
100
JCMETH002 MRM of 6 Channels ES+ 
342 > 166
1.44e4
1.681.630.88
1.08 1.25
JCMETH002 MRM of 6 Channels ES+ 
166 > 107.2
2.02e6
0.85
1.03
JCMETH002 MRM of 6 Channels ES+ 
155.1 > 92.2
1.95e6
1.18
JCMETH002 MRM of 6 Channels ES+ 
152 > 107
2.17e4
1.03
6.263.61 8.79
JCMETH002 MRM of 6 Channels ES+ 
150.2 > 91
3.57e7
1.20
JCMETH002 MRM of 6 Channels ES+ 
136 > 91
9.16e6
1.13
a 
b 
c 
d 
e 
f 
a) METH-4-O-glucuronide; b) 4-OH-METH; c) METH-D5; d) 4-OH-AMP; e) METH; f) 
AMP 
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 The peaks of six samples from extraction method 1 were integrated and the 
average retention times and peak areas of the samples are provided in Table 1. 
 
Table 1: Method 1 LC-MS/MS Results 
 
 tR is the retention time; PA is the peak area 
 
 
3.2 Method 2 results 
 The mass spectrometer was set to detect the same compounds as method 1. 
The chromatogram of a sample from method 2 is shown in Figure 3. 
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Figure 3: Method 2 Chromatogram 
Urine hph gluc 01-3 from method 1
Time
1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00
%
0
100
1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00
%
0
100
1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00
%
0
100
1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00
%
0
100
1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00
%
0
100
1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00
%
0
100
1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00
%
0
100
JCMETH036 MRM of 7 Channels ES+ 
342 > 166
1.51e4
1.690.84
2.61
JCMETH036 MRM of 7 Channels ES+ 
245.1 > 165.1
1.32e4
1.25
4.491.72 1.93
3.343.252.52
3.46
3.64 3.96
4.61
5.445.17 5.50 6.82
JCMETH036 MRM of 7 Channels ES+ 
166 > 107.2
1.73e5
0.84
1.04
JCMETH036 MRM of 7 Channels ES+ 
155.1 > 92.2
7.18e5
1.10
JCMETH036 MRM of 7 Channels ES+ 
152 > 107
4.85e3
1.10
1.691.51 1.90 2.16 3.553.342.37 3.17 8.656.264.053.99 4.49 6.204.88 5.08 5.76 6.59
6.76
7.417.32 7.59 8.15 10.158.94 9.27 9.83 10.6010.68
JCMETH036 MRM of 7 Channels ES+ 
150.2 > 91
1.35e7
1.10
JCMETH036 MRM of 7 Channels ES+ 
136 > 91
2.02e6
1.10
a 
b 
c 
d 
e 
f 
g 
a) METH-4-O-glucuronide; b) METH-4-O-sulfate; c) 4-OH-METH; d) METH-D5; e) 4-
OH-AMP; f) METH; g) AMP 
   
 The peaks for 8 samples extracted using method 2 were integrated and the 
retention times and peak areas are provided in Table 2. 
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Table 2: Method 2 LC-MS/MS Results 
 
tR is retention time; PA is peak area 
 
 
3.3 Method 3 results 
 For method 3, the mass spectrometer was set to detect peaks of METH-4-O-
glucuronide, METH-4-O-sulfate, 4-OH-METH, 4-OH-AMP, METH, and AMP. The 
chromatogram of a method 3 extraction sample is shown in Figure 4. 
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Figure 4: Method 3 Chromatogram 
Urine hph gluc 01-2 from method 3
Time
1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00
%
0
100
1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00
%
0
100
1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00
%
0
100
1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00
%
0
100
1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00
%
0
100
1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00
%
0
100
1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00
%
0
100
JCMETH031 MRM of 7 Channels ES+ 
342 > 166
7.61e4
0.87
1.69
JCMETH031 MRM of 7 Channels ES+ 
245.1 > 165.1
2.17e4
4.61
1.25
1.07 3.251.43 1.75 2.07 2.52
3.46
4.204.11 5.175.41
JCMETH031 MRM of 7 Channels ES+ 
166 > 107.2
8.62e5
1.01
JCMETH031 MRM of 7 Channels ES+ 
155.1 > 92.2
1.57e3
1.01 1.16
10.6610.571.841.54 5.644.113.22
3.081.96 2.812.19 3.31 4.02 4.674.20 4.93 5.08 6.206.14 7.327.236.946.56 8.337.94
7.74 8.41 10.159.339.09 9.68 10.74
JCMETH031 MRM of 7 Channels ES+ 
152 > 107
3.64e4
0.98
1.13
2.251.721.96
JCMETH031 MRM of 7 Channels ES+ 
150.2 > 91
2.61e7
1.10
JCMETH031 MRM of 7 Channels ES+ 
136 > 91
4.74e6
1.07
a 
b 
c 
d 
e 
f 
g 
a) METH-4-O-glucuronide; b) METH-4-O-sulfate; c) 4-OH-METH; d) METH-D5; e) 4-
OH-AMP; f) METH; g) AMP 
 
  
 The peaks for 6 samples from a method 3 extraction were integrated and the 
retention times and peak areas are provided in Table 3. 
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Table 3: Method 3 LC-MS/MS Results 
 
tR is retention time; PA is peak area 
 
3.4 Method 4 results 
 For method 4, the mass spectrometer was set to detect peaks of METH-4-O-
glucuronide, METH-4-O-sulfate, 4-OH-METH, 4-OH-AMP, METH, and AMP. For each 
sample of urine, the glucuronide and sulfate were eluted separately. A chromatogram of 
a glucuronide fraction and a sulfate fraction are shown in Figure 5 and Figure 6 
respectively. 
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Figure 5: Method 4 Chromatogram Glucuronide Fraction 
Urine hph gluc 03-4 from method 4 glucuronides
Time
1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00
%
0
100
1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00
%
0
100
1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00
%
0
100
1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00
%
0
100
1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00
%
0
100
1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00
%
0
100
JCMETH029 MRM of 7 Channels ES+ 
342 > 166
1.22e5
1.69
1.10 1.96 2.55
JCMETH029 MRM of 7 Channels ES+ 
245.1 > 165.1
2.86e5
4.58
3.371.22 1.75 4.14 5.41
JCMETH029 MRM of 7 Channels ES+ 
166 > 107.2
8.64e4
0.98
2.281.13 2.041.721.48 2.81
2.69
4.32
JCMETH029 MRM of 7 Channels ES+ 
152 > 107
7.36e3
0.95
2.281.931.691.48
1.10
3.462.46
3.172.99 4.174.11 4.52 5.324.70 4.96 5.41 6.676.59 6.85 9.519.339.007.56 8.447.77 10.39
9.659.89 10.71
JCMETH029 MRM of 7 Channels ES+ 
150.2 > 91
4.09e6
1.10
JCMETH029 MRM of 7 Channels ES+ 
136 > 91
4.14e5
1.10
1.04
a 
b 
c 
d 
e 
f 
a) METH-4-O-glucuronide; b) METH-4-O-sulfate; c) 4-OH-METH; d) 4-OH-AMP; e) 
METH; f) AMP 
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Figure 6: Method 4 Chromatogram Sulfate Fraction 
a) METH-4-O-glucuronide; b) METH-4-O-sulfate; c) 4-OH-METH; d) 4-OH-AMP; e) 
METH; f) AMP 
Urine hph gluc03-4 from method 4 sulfates
 
 Peaks for 6 samples extracted using method 4 were integrated and the retention 
times and peak areas are provided in Table 4. 
 
 
 
Time
1.00  2.00 3.00 4.00  5.00 6.00 7.00 8.00 9.00  10.00
%
0
100
1.00  2.00 3.00 4.00  5.00 6.00 7.00 8.00 9.00  10.00
%
0
100
1.00  2.00 3.00 4.00  5.00 6.00 7.00 8.00 9.00  10.00
%
0
100
1.00  2.00 3.00 4.00  5.00 6.00 7.00 8.00 9.00  10.00
%
0
100
1.00  2.00 3.00 4.00  5.00 6.00 7.00 8.00 9.00  10.00
%
0
100
1.00  2.00 3.00 4.00  5.00 6.00 7.00 8.00 9.00  10.00
%
0
100
1.00  2.00 3.00 4.00  5.00 6.00 7.00 8.00 9.00  10.00
%
0
100
JCMETH010 MRM of 7 Channels ES+ 
342 > 166
4.66e3
0.75 
0.89 6.351.661.04 5.264.29 5.945.47
JCMETH010 MRM of 7 Channels ES+ 
245.1 > 165.1
1.65e3
0.92
1.96 1.25  1.87 2.46 2.07  3.253.022.90 4.553.493.643.84  8.715.505.174.67 5.85 6.536.44 8.096.917.00 7.85 8.41 10.019.009.21 7.29 9.56  10.48
JCMETH010 MRM of 7 Channels ES+ 
166 > 107.2
3.94e4
2.10
1.070.92
9.03 6.97
JCMETH010 MRM of 7 Channels ES+ 
155.1 > 92.2
1.30e3
1.25 
0.98 
0.87
9.864.732.19 1.572.02  4.14 3.96 3.643.08 2.522.90 8.337.595.445.11 7.506.11 6.47 7.156.88 7.858.09 9.59 9.008.41 
9.98
10.63
JCMETH010 MRM of 7 Channels ES+ 
152 > 107
1.96e4
1.01 
1.72 
JCMETH010 MRM of 7 Channels ES+ 
150.2 > 91
1.87e6
1.28 
JCMETH010 MRM of 7 Channels ES+ 
136 > 91
7.21e4
1.19 
0.69 0.95  4.05 2.96 2.342.10 2.63  4.344.64 7.796.386.17 7.656.85 9.95 8.00 10.68
a 
f 
g 
b 
c 
d 
e 
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Table 4: Method 4 LC-MS/MS Results 
 
 
tR is retention time; PA is peak area 
 
 
3.5 Acid Hydrolysis Results 
 For the acid hydrolysis method, the mass spectrometer was set to use the same 
method as method 4. The chromatogram of a sample treated with HCl before extraction 
is shown in Figure 7. 
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Figure 7: Acid Hydrolysis Chromatogram 
Urine hph gluc 01-3 method 4 glucuronide HCl
Time
1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00
%
0
100
1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00
%
0
100
1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00
%
0
100
1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00
%
0
100
1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00
%
0
100
1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00
%
0
100
1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00
%
0
100
JCMETH051 MRM of 7 Channels ES+ 
342 > 166
8.82e4
1.69
1.01 5.64
JCMETH051 MRM of 7 Channels ES+ 
245.1 > 165.1
4.14e5
3.73
1.28 2.781.78
4.85
5.50
JCMETH051 MRM of 7 Channels ES+ 
166 > 107.2
2.09e5
0.95
2.371.841.16
JCMETH051 MRM of 7 Channels ES+ 
155.1 > 92.2
782
0.92
9.951.13 3.493.401.28 2.552.021.931.48 2.46 2.93 2.99
9.038.068.003.58 7.717.326.233.84 4.29 4.67 6.035.50 6.826.76 8.12 8.77 9.809.30 9.36
10.4510.60
JCMETH051 MRM of 7 Channels ES+ 
152 > 107
1.38e4
0.95
1.69
1.51
1.96
2.46 3.613.22 7.067.004.434.34 6.765.85 9.127.85 9.839.56
9.95
10.57
JCMETH051 MRM of 7 Channels ES+ 
150.2 > 91
1.23e7
1.10
JCMETH051 MRM of 7 Channels ES+ 
136 > 91
5.46e5
1.07
a 
b 
c 
d 
e 
f 
g 
a) METH-4-O-glucuronide; b) METH-4-O-sulfate; c) 4-OH-METH; d) METH-D5; e) 4-
OH-AMP; f) METH; g) AMP 
 
  
 Peaks for 3 samples treated with HCl and 3 samples untreated with HCl have 
been integrated and the retention times and peak areas are provided in Table 5. 
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Table 5: Acid Hydrolysis LC-MS/MS Results 
 
 
tR is retention time; PA is peak area 
 
3.6 Blank Urine 
 Urine from rats that were not administered METH was extracted using method 4. 
The chromatogram of a glucuronide faction and a sulfate fraction are shown in Figure 8 
and Figure 9 respectively.  
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Figure 8 : Blank Sample Chromatogram Glucuronide Fraction 
Urine hph gluc Blank Glucuronide 2
Time
1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00
%
0
100
1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00
%
0
100
1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00
%
0
100
1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00
%
0
100
1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00
%
0
100
1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00
%
0
100
JCMETH084 MRM of 6 Channels ES+ 
342.1 > 166
6.45e4
1.53
1.47
1.69
0.95 1.06 5.072.85 3.29 5.50 9.949.15
JCMETH084 MRM of 6 Channels ES+ 
245.1 > 165.1
1.66e4
1.53
1.45
1.251.19
2.01
1.71 4.914.852.13 4.393.192.33 3.15 4.133.38 4.01
5.03
5.60 5.68 5.94 6.656.27 6.98 10.038.327.23 7.64 8.20 8.38
9.809.189.14 9.62 10.58
10.73
10.99
JCMETH084 MRM of 6 Channels ES+ 
166 > 107.2
6.41e3
1.21
1.15
1.30 2.361.561.80 5.684.393.633.232.50 2.57 3.73 5.445.034.97 6.476.385.79 9.999.177.477.046.57 7.55 8.358.14 8.41
8.77 9.889.26 10.1410.36 10.77
JCMETH084 MRM of 6 Channels ES+ 
152 > 107
7.66e3
1.59
1.271.22
1.65
4.48
1.72 2.602.33 3.04
3.39 3.57 4.294.21
4.56
5.10 10.4110.115.20 5.48 7.586.546.505.83 7.186.88 9.738.808.368.26 9.15 9.58 10.77 10.89
JCMETH084 MRM of 6 Channels ES+ 
150.2 > 91
3.67e4
5.441.88
1.47
3.47
2.802.632.19 5.134.394.073.86 4.60 6.415.77
6.18
9.858.827.03 7.35 7.82 10.7610.12
JCMETH084 MRM of 6 Channels ES+ 
136 > 91
3.72e4
2.15
1.441.30 1.69
2.19
2.452.50 2.85
3.48 3.65 4.543.864.48 5.03 5.57 10.68
a 
b 
c 
d 
e 
f 
a) METH-4-O-glucuronide; b) METH-4-O-sulfate; c) 4-OH-METH; d) 4-OH-AMP; e) 
METH; f) AMP 
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Figure 9 : Blank Sample Chromatogram Sulfate Fraction 
Urine hph gluc Blank Sulfate 4
Time
1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00
%
0
100
1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00
%
0
100
1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00
%
0
100
1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00
%
0
100
1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00
%
0
100
1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00
%
0
100
JCMETH091 MRM of 6 Channels ES+ 
342.1 > 166
3.55e3
0.97
1.531.04
6.801.92 2.981.98
2.50 5.03
3.16
4.604.273.35 3.79
6.68
5.655.53 5.94 6.17 8.807.12 7.44 8.718.278.037.65
8.97
9.809.58 10.8510.14 10.52 10.93
JCMETH091 MRM of 6 Channels ES+ 
245.1 > 165.1
3.53e5
1.47
1.97
JCMETH091 MRM of 6 Channels ES+ 
166 > 107.2
2.47e3
4.981.54
1.221.15
4.591.60 4.062.09 3.772.21 3.062.83 3.63
4.41 4.86
10.027.806.766.645.21 6.075.36 5.82 7.00 7.087.32 8.718.11
8.27 9.999.538.92 10.50 10.59 10.94
JCMETH091 MRM of 6 Channels ES+ 
152 > 107
4.22e3
1.51
1.12
1.57
1.65
4.382.532.19 3.503.132.76 3.71 3.97 8.385.944.65 5.04 5.645.54 7.896.38 7.427.067.00
7.77 7.94 10.3810.008.988.58
9.809.47 10.53 10.86
JCMETH091 MRM of 6 Channels ES+ 
150.2 > 91
5.02e3
3.48
2.801.921.330.97
1.72 2.33 2.86
5.45
3.57
4.264.21 5.335.094.76
6.455.826.06 9.507.586.86 7.47 8.95
8.73
7.65 8.55 10.27
10.03
10.67 10.76
JCMETH091 MRM of 6 Channels ES+ 
136 > 91
2.25e4
2.12
0.88
1.38 1.53
2.21
4.512.972.80 3.563.47 4.123.86 4.74 5.235.35 5.88 10.9910.3910.265.926.17 8.27
a 
b 
c 
d 
e 
f 
a) METH-4-O-glucuronide; b) METH-4-O-sulfate; c) 4-OH-METH; d) 4-OH-AMP; e) 
METH; f) AMP 
 
The peaks for 6 extracted samples were integrated and the retention times and peak 
areas are provided in Table 6. 
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Table 6 : Blank Sample LC-MS/MS Results 
 
No peaks were detected for the compounds of interest.  
 
4. Discussion 
 
4.1 Extraction Methods 1, 2, and 3 
 Methods 1 through 3 were able to extract glucuronide and sulfate, however the 
extraction recovery was poor. Samples extracted using Method 1 contained very large 
amounts of METH and AMP which could be reduced. Method 2 aided in the cleanup in 
the samples to some extent but as more barium hydroxide was added to the samples, 
the amount of glucuronide extracted decreased. This can be attributed to the fact that 
as more barium hydroxide was added, the pH increased to a high of 13. This occurred 
when 450 μl of 6 M barium hydroxide was added. At this pH, the integrity of the C18 
stationary phase was compromised. In method 3, LC-MS/MS data showed similar 
recovery of the peak at 1.7 min (i.e. the glucuronide). The method used a surfactant 
which is often not appropriate or favorable for a mass spectrometer and therefore 
optimization of this method was not pursued. In fact the extraction of the glucuronide 
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might have been high with method 3, but the MS signal might have been compromised 
due to the presence of the surfactant. 
 
4.2 Extraction method 4, acid hydrolysis and blank urine 
 Method 4 was able to produce large quantities of the phase II metabolites of 
METH and relatively clean samples. The amount of glucuronide detected in the samples 
extracted using method 4 were at a minimum increased by a factor of four compared to 
the other methods. It was designed to separate the glucuronide and sulfate into two 
fractions, however, LC-MS/MS data suggested that the sulfates came off the column in 
the glucuronide fraction in almost all cases. The sulfate fraction was of no use in 
extracting the phase II metabolites. Multiple peaks occurred in some cases, but after 
comparison with other method’s data, it is evident that the glucuronide retention time is 
1.69 min and the sulfate retention time is 4.61 min. The confirmation that these peaks 
are the glucuronide and sulfate metabolites comes from the acid hydrolysis results. If 
the glucuronide and sulfate were what was being detected by the mass spectrometer at 
the retention times that occurred, acid hydrolyzed samples would either not detect the 
corresponding peaks, or the peaks would have a lower peak area. Also, as the 
glucuronides and sulfates are hydrolyzed, the by-products are a glucuronic acid or 
sulfate and a 4-OH-METH. Because of this, it is expected that if the glucuronide and 
sulfate are being hydrolyzed, the amount of 4-OH-METH detected would increase. The 
samples that were subjected to acid hydrolysis showed peaks at the same retention 
time as the suspected phase II metabolites that were reduced by approximately half 
compared to untreated samples and the peak area for 4-OH-METH increased as 
expected. This supports the idea that the glucuronide fraction elutes from the column at 
21 
 
1.69 min and the sulfate fraction elutes from the column at 4.61 min and that the phase 
II metabolites are what is being detected. Also, urine used as blank samples provide 
more confirmation of the presence of the phase II metabolites. Blank urine should not 
contain glucuronide or sulfate of METH, therefore if the sample does not contain the 
peak thought of to be the glucuronide or sulfate, the data would suggest that the peaks 
detected in urine containing METH are indeed the glucuronide and sulfate. The LC-
MS/MS data from the blank urine samples did not contain the peak at the suspected 
retention time of the glucuronide or sulfate and therefore further confirms the presence 
of the glucuronide and sulfate of METH. 
 
4.3 Future studies 
 This study suggests that Method 4 was the most effective method for the 
purpose of sample preparation. In the future, this method will be used to isolate the 
glucuronide to be used as a standard. The isolated fractions will then be analyzed using 
nuclear magnetic resonance (NMR) spectroscopy for further confirmation of the 
structural details of 4-O-METH-Glucuronide and 4-O-METH-Sulfate. Isolation of these 
phase II metabolites will also provide a more complete description of the disposition of 
methamphetamine and it’s potentially active metabolites. 
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